#USA #Menlo Park #Obesity Treatment #Phenomix Sciences #MyPhenome Test

Introduction

In a groundbreaking set of studies presented at the Digestive Disease Week (DDW) 2026, focused on advancing the field of precision obesity medicine, researchers from Mayo Clinic have demonstrated the efficacy of the MyPhenome test. This innovative tool showcases its potential to influence treatment strategies for obesity by utilizing an individual’s unique biology to predict outcomes across various treatment modalities, including pharmacological approaches and surgical interventions.

The Significance of the Studies

No longer can obesity be treated with a one-size-fits-all methodology; the studies underscore the importance of personalized medicine in effectively addressing this widespread health issue. Conducted by a team led by Dr. Andres Acosta, a physician scientist at Mayo Clinic and co-founder of Phenomix Sciences, these studies bolster the argument for tailored treatment plans that resonate with the patient’s biological makeup.

Study Breakdown

The first study titled "Performance of a Machine Learning–Assisted Gene Risk Score for Calories-to-Satiation to Predict Weight Loss After Sleeve Gastrectomy: 10-Year Experience," focuses on a decade's worth of data accumulated from patients who underwent sleeve gastrectomy. This research uncovers variations in weight loss outcomes between two distinct groups identified by the MyPhenome test: the Hungry Brain and Hungry Gut groups. Patients in the Hungry Brain cohort exhibited a significant long-term weight loss, maintaining on average a 29.4% reduction in total body weight, compared to 26.6% in the Hungry Gut group, illustrating the test's predictive capabilities and clinical relevance.

By four years post-surgery, the distinction became even more pronounced, with Hungry Brain patients experiencing a 22.7% weight loss juxtaposed to 17.0% in Hungry Gut participants. Impressively, 70% of those in the Hungry Brain category accomplished a total body weight loss of 20% or more at the two-year mark, a figure that remained consistent over the course of the ensuing years.

Biological Heterogeneity Examination

The second study examines the biological heterogeneity of obesity titled "Obesity Sub-Phenotype with Reduced GLP-1 and Fast Gastric Emptying is Associated with Weight Loss Response to Tirzepatide." It revealed that patients classified with a specific subphenotype characterized by rapid gastric emptying and low GLP-1 secretion rates achieved an outstanding 21.5% total body weight loss at six months when treated with tirzepatide, nearly doubling the weight reduction seen in those with average GLP-1 levels.

Implications for Obesity Treatment

With these studies, the researchers enhance the dialogue surrounding obesity as a heterogeneous disease that demands personalized treatment strategies. Dr. Acosta emphasizes that an individual's understanding of their unique biological background plays a crucial role in determining the most effective treatment route. By employing the MyPhenome test, medical professionals can ensure that therapeutic interventions are aligned with each patient’s genetic predispositions.

The Path Towards Precision Medicine

The findings from these studies reaffirm the clinical value of the MyPhenome test, which utilizes a straightforward saliva sample to uncover the biological underpinnings contributing to obesity in patients. Phenomix Sciences, the biotechnology company at the forefront of this innovation, aims to revolutionize obesity management through insights derived from advanced genetic testing and analytics.

Mark Bagnall, CEO of Phenomix Sciences, articulates the broader impact of this research, asserting that the data emerging from these studies significantly illustrates how precision obesity medicine can alter therapeutic choices and strategies. This commitment to patient-centered care not only helps in formulating more tailored therapeutic approaches but also aids in optimizing pharmaceutical trials to identify populations that are likely to respond favorably to specific treatments.

Conclusion

In summary, the new findings from Mayo Clinic signify a pivotal step towards making personalized obesity management a reality. By tapping into the diverse biological factors that influence obesity, the MyPhenome test stands as a beacon for pushing the boundaries of traditional obesity treatment methods, offering hope for lasting and meaningful weight loss outcomes.